Search

To assess the mortality, readmission rates, and practice variation of percutaneous cholecystostomy (PC) in patients with acute calculous cholecystitis in the United Kingdom (UK).A total of 1,186 consecutive patients (636 men [53.6%]; median age, 75 years; range, 24-102 years) who underwent PC for acute calculous cholecystitis between January 1, 2019, and December 31, 2020, were included from 36 UK hospitals. The exclusion criteria were diagnostic aspirations, absence of acute calculous cholecystitis, and age less than 16 years. The coronavirus disease 2019 (COVID-19) lockdown was declared on March 26, 2020, in the UK, which served to distinguish among groups.Most patients (66.3%) underwent PC as definitive treatment, whereas 31.3% underwent PC as a bridge to surgery. The overall 30-day readmission rate was 42.2% (500/1,186), and the 30-day mortality was 9.1% (108/1,186). Centers performing fewer than 30 PCs per year had higher 90-day mortality than those performing more than 60 (19.3% vs 11.0%, respectively; P = .006). A greater proportion of patients presented with complicated acute calculous cholecystitis during the COVID-19 pandemic compared to prior (49.9% vs 40.9%, respectively; P = .007), resulting in more PCs (61.3 vs 37.9 per month, respectively; P.001). More PCs were performed in tertiary hospitals than in district general hospitals (9 vs 3 per 100 beds, respectively; P.001), with a greater proportion performed as a bridge to surgery (50.5% vs 22.8%, respectively; P.001).The practice of PC is highly variable throughout the UK. The readmission rates are high, and there is significant correlation between mortality and PC case volume.

Bevacizumab is a monoclonal antibody against vascular endothelial growth factor (VEGF) widely used in clinical oncology. Bevacizumab is commonly co-adminis- tered with chemotherapy. It is recommended that the first infusion of the antibody last 90 min, the second 60 and all subsequent 30 min. Since there is no clear rationale for the proposed schedule of administration, our study assessed the feasibility of a 30 min initial infusion.Cancer patients eligible for de novo bevacizumab treatment were enrolled. All patients received standard bevacizumab dose of 5, 7.5 or 10 mg/kg according to the indication, diluted in 250 ml normal saline, as a 30-min intravenous infusion.Thirty two patients were enrolled: male 18, female 14, median age 58 years, range 42-78. Oncologic diagnosis: lung cancer 16, colorectal 4, breast 3, ovarian 7, renal 2. All patients tolerated the infusion well. No hypersensitivity reactions were noted. Mean systolic and diastolic blood pressures were 122 and 73 mm/Hg respectively prior to the infusion and 125 and 75 mm/Hg 15 min after the infusion (p=0.3). During the observation period of 1 hour, blood pressure did not change. Transient grade 3 systolic hypertension was noted in 1 patient, with spontaneous regression in 45 min.Rapid administration of bevacizumab in 30 min, rather than the recommended in the package insert 90 min is feasible and safe. Such a practice limits the time of confinement in the treatment area to patients' satisfaction and would result in cost savings by reducing health resource utilization.